Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity.

Citation data:

Journal of controlled release : official journal of the Controlled Release Society, ISSN: 1873-4995, Vol: 263, Page: 172-184

Publication Year:
Usage 150
Abstract Views 149
Clicks 1
Captures 22
Readers 22
Mentions 22
Blog Mentions 12
Q&A Site Mentions 5
News Mentions 5
Social Media 3538
Shares, Likes & Comments 3523
Tweets 15
Citations 6
Citation Indexes 6
Yuan, Dongfen; Yi, Xiang; Zhao, Yuling; Poon, Chi-Duen; Bullock, Kristin M; Hansen, Kim M; Salameh, Therese S; Farr, Susan A; Banks, William A; Kabanov, Alexander V
Elsevier BV
Pharmacology, Toxicology and Pharmaceutics
Most Recent Tweet View All Tweets
Most Recent Blog Mention
Most Recent News Mention
article description
Leptin is an adipocyte-secreted hormone that is delivered via a specific transport system across the blood-brain barrier (BBB) to the brain where it acts on the hypothalamus receptors to control appetite and thermogenesis. Peripheral resistance to leptin due to its impaired brain delivery prevents therapeutic use of leptin in overweight and moderately obese patients. To address this problem, we modified the N-terminal amine of leptin with Pluronic P85 (LepNP85) and administered this conjugate intranasally using the nose-to-brain (INB) route to bypass the BBB. We compared this conjugate with the native leptin, the N-terminal leptin conjugate with poly(ethylene glycol) (LepNPEG5K), and two conjugates of leptin with Pluronic P85 attached randomly to the lysine amino groups of the hormone. Compared to the random conjugates of leptin with P85, LepNP85 has shown higher affinity upon binding with the leptin receptor, and similarly to native hormone activated hypothalamus receptors after direct injection into brain. After INB delivery, LepNP85 conjugate was transported to the brain and accumulated in the hypothalamus and hippocampus to a greater extent than the native leptin and LepNPEG5K and activated leptin receptors in hypothalamus at lower dose than native leptin. Our work suggests that LepNP85 can access the brain directly after INB delivery and confirms our hypothesis that the improvement in brain accumulation of this conjugate is due to its enhanced brain absorption. In conclusion, the LepNP85 with optimized conjugation chemistry is a promising candidate for treatment of obesity.